Cenetron’s flow cytometry technology aids in immune response characterization, patient classification and more.
This technology allows for the precise characterization of immune responses, identification of biomarkers, and evaluation of treatment efficacy, aiding in patient stratification, monitoring of drug effects and optimization of therapeutic strategies.
Versiti Clinical Trials’ flow cytometry capability at Cenetron determines absolute counts and percentages for the following cell types:
- CD3+ T-cells
- CD4+ T-cells
- CD8+ T-cells
- CD19+ B-cells
- CD56/16+ NK-cells
Assessment of immune lymphocytes requires expedient testing (typically within 72 hours) of fresh whole blood samples by flow cytometry, playing a crucial role in enhancing the accuracy and efficiency of clinical trials. This testing aids in improved patient outcomes and the development of more targeted and effective treatments.